{
  "compound": "Nabilone",
  "condition": "PARKINSONS",
  "effect_size": "Sustained benefit in responders",
  "study_type": "OBSERVATIONAL",
  "source": "NORML:PD_OBSERVATIONAL_006",
  "participants": "22 PD patients (responders from prior NMS-Nab trial)",
  "year": 2024,
  "notes": "Long-term Safety and Efficacy of Open-Label Nabilone on Sleep and Pain in Parkinson's Disease",
  "confidence": "medium",
  "abstract": "Nabilone was generally well tolerated; sustained improvements reported in overall NMS burden (CGI-I) and significant improvements in sleep and pain outcomes over 6 months"
}